0.306

1.32% 0.004

Fibrogen Inc (FGEN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché FGEN Giù? Forum Previsione

Precedente Chiudi:

$0.302

Aprire:

$0.3

Volume 24 ore:

585.99K

Relative Volume:

0.19

Capitalizzazione di mercato:

$30.92M

Reddito:

$147.75M

Utile/perdita netta:

$-284.23M

Rapporto P/E:

-0.1044

EPS:

-2.93

Flusso di cassa netto:

$-317.54M

1 W Prestazione:

-0.65%

1M Prestazione:

+10.23%

6M Prestazione:

-8.57%

1 anno Prestazione:

-75.32%

Intervallo 1D:

$0.30

$0.3104

Intervallo di 1 settimana:

$0.29

$0.32

Portata 52W:

$0.18

$1.53

Fibrogen Inc Stock (FGEN) Company Profile

Nome

Fibrogen Inc

Settore

Healthcare (1170)

Industria

Biotechnology (671)

Telefono

415-978-1200

Indirizzo

350 BAY STREET, SAN FRANCISCO, CA

Dipendente

225

Cinguettio

@FibroGenInc

Prossima data di guadagno

2025-03-17

Ultimi documenti SEC

FGEN's Discussions on Twitter

Confronta FGEN con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
FGEN Fibrogen Inc	0.306	31.08M	147.75M	-284.23M	-317.54M	-2.93
ONC Beigene Ltd Adr	228.38	25.07B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	438.65	109.14B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.27	36.39M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	594.32	56.98B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	71.31	5.39B	0	-153.72M	-103.81M	-2.00

Fibrogen Inc Stock (FGEN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-08-08	Downgrade	BofA Securities	Neutral → Underperform
2023-06-26	Downgrade	BofA Securities	Buy → Neutral
2023-06-26	Downgrade	Raymond James	Outperform → Mkt Perform
2023-06-26	Downgrade	Stifel	Buy → Hold
2023-06-26	Downgrade	William Blair	Outperform → Mkt Perform
2023-06-02	Aggiornamento	Stifel	Hold → Buy
2023-01-31	Aggiornamento	William Blair	Mkt Perform → Outperform
2023-01-26	Aggiornamento	Raymond James	Mkt Perform → Outperform
2023-01-05	Aggiornamento	BofA Securities	Neutral → Buy
2021-09-22	Downgrade	Goldman	Neutral → Sell
2021-08-20	Aggiornamento	Raymond James	Underperform → Mkt Perform
2021-07-16	Downgrade	BofA Securities	Buy → Neutral
2021-07-16	Downgrade	Stifel	Buy → Hold
2021-04-07	Downgrade	H.C. Wainwright	Buy → Neutral
2021-04-07	Downgrade	Mizuho	Buy → Neutral
2021-03-31	Aggiornamento	BofA Securities	Neutral → Buy
2021-03-02	Downgrade	Jefferies	Buy → Hold
2021-02-01	Iniziato	H.C. Wainwright	Buy
2020-10-26	Iniziato	Raymond James	Underperform
2020-07-10	Ripresa	Stifel	Buy
2020-05-01	Iniziato	Cowen	Market Perform
2020-04-27	Iniziato	BofA/Merrill	Neutral
2019-05-29	Ripresa	Goldman	Neutral
2019-05-10	Downgrade	William Blair	Outperform → Mkt Perform
2019-04-12	Iniziato	Piper Jaffray	Neutral
2019-02-11	Ripresa	Stifel	Buy
2018-12-19	Aggiornamento	Citigroup	Neutral → Buy
2017-08-08	Reiterato	Leerink Partners	Outperform
2017-08-08	Reiterato	Stifel	Buy
2017-07-21	Downgrade	Goldman	Buy → Neutral
2017-07-11	Iniziato	Jefferies	Buy
2016-02-11	Aggiornamento	Credit Suisse	Neutral → Outperform
2016-01-21	Iniziato	Credit Suisse	Neutral
2015-12-04	Iniziato	Citigroup	Buy
2015-09-23	Iniziato	Lake Street	Hold
2015-07-29	Iniziato	Citigroup	Buy
2015-07-20	Aggiornamento	Goldman	Neutral → Buy
2014-12-09	Iniziato	Stifel	Buy

Mostra tutto

Fibrogen Inc Borsa (FGEN) Ultime notizie

12:09 PM

FibroGen outlines $185M China divestiture and extended cash runway into 2027 while advancing prostate cancer pipeline - MSN

12:09 PM

May 16, 2025

FibroGen Q1 2025 slides: China sale to extend cash runway amid revenue decline By Investing.com - Investing.com South Africa

May 16, 2025

FibroGen First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 16, 2025

FibroGen Q1 2025 slides: China sale to extend cash runway amid revenue decline - Investing.com Australia

May 16, 2025

May 15, 2025

FibroGen Inc earnings beat by $0.15, revenue fell short of estimates - Investing.com UK

May 13, 2025